Just as for NAFLD, these preclinical findings emphasize the potential role of CB1R in the worsening process of ALD, making it a potential therapeutic target to alleviate ALD (Figure 1). Here, CNR1 is linked to metabolic dysfunction-associated steatotic liver disease.